Bupivacaine + betamethasone sodium phosphate

Bupivacaine + betamethasone sodium phosphate is a pharmacological combination consisting of a long-acting amide local anesthetic and a synthetic glucocorticoid (PubChem CID 2474, 23200). This combination is frequently employed in clinical settings, particularly in orthopedics and pain management, for local or intra-articular injections to provide rapid and sustained relief from pain and inflammation (StatPearls: Bupivacaine). Bupivacaine works by binding to the intracellular subunit of voltage-gated sodium channels, effectively blocking the influx of sodium ions and preventing the generation and conduction of nerve impulses (PubMed: PMID 30020606). Betamethasone sodium phosphate acts as a potent agonist of the glucocorticoid receptor (NR3C1), leading to the modulation of gene expression that reduces the production of pro-inflammatory cytokines and enzymes (DrugBank: Betamethasone). This dual-action approach is effective for treating conditions such as osteoarthritis, bursitis, and postoperative pain. However, clinicians must be mindful of potential safety concerns, including local anesthetic systemic toxicity (LAST), hyperglycemia, and the risk of chondrotoxicity associated with corticosteroid exposure in joint spaces (PubMed: PMID 28403345).

Other names

Bupivacaine and betamethasone combinationBupivacaine-betamethasone sodium phosphateLocal anesthetic and corticosteroid combination

Bupivacaine inhibits voltage-gated sodium channels to block nerve conduction, while betamethasone sodium phosphate activates glucocorticoid receptors to suppress inflammatory gene expression (StatPearls, DrugBank).